Innovations, challenges, and minimal information for standardization of humanized mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mice xenotransplanted with human cells and/or expressing human gene products (also known as "humanized mice") recapitulate the human evolutionary specialization and diversity of genotypic and phenotypic traits. These models can provide a relevant in vivo context for understanding of human-specific physiology and pathologies. Humanized mice have advanced toward mainstream preclinical models and are now at the forefront of biomedical research. Here, we considered innovations and challenges regarding the reconstitution of human immunity and human tissues, modeling of human infections and cancer, and the use of humanized mice for testing drugs or regenerative therapy products. As the number of publications exploring different facets of humanized mouse models has steadily increased in past years, it is becoming evident that standardized reporting is needed in the field. Therefore, an international community-driven resource called "Minimal Information for Standardization of Humanized Mice" (MISHUM) has been created for the purpose of enhancing rigor and reproducibility of studies in the field. Within MISHUM, we propose comprehensive guidelines for reporting critical information generated using humanized mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 1×
“Organoid technology allows the generation of unlimited numbers of non-malignant (Sampaziotis et al, 2017) or cancer cells (Broutier et al, 2017; Fig 1B, Table 1).”
BackgroundSelf-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · cited 1×
“…(Byrne et al, 2017). ª 2020 The Authors EMBO Molecular Medicine 12: e8662 | 2020 9 of 16 Finally, vast PDX collections are poised to capture inter-patient tumor diversity on a population scale, thus representing powerful platforms for large-scale genotype–response associations (Gao et al, 2015).”
BackgroundIsolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment
Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., & Dick, J. E. (2011) · Science · doi:10.1126/science.1201219 · Cited by 919 · cited 1×
“Therapeutic modulation of the human immune system to improve recognition and response to tumors is a clinically accepted revolution in oncology treatment for multiple tumor types (Pardoll, 2012).”
BackgroundRobust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Development and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789 · cited 3×
“Another method to improve and accelerate the regeneration of human T and B cells in HIS mice is the adoptive transfer of geneengineered human DCs from the HSC donor that are long-lived in vivo (Salguero et al, 2014; Daenthanasanmak et al, 2015; Volk et al, 2017).”
BackgroundMethodHolt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G. M., Kohn, D. B., Gregory, P. D., Holmes, M. C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1663 · Cited by 677
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“These IO studies have been used, for example, to test immune modulation caused by engineered agonistic or antagonistic monoclonal antibodies (mAb; Scott et al, 2012), bispecific T-cell engagers (BiTE; Baeuerle & Reinhardt, 2009), or T-cell bispecific antibodies (TCB; Bacac et al, 2018).”
MethodWunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415 · cited 1×
“In order to further humanize xenograft models, transgenic and knock-in strains have been generated that (over)express growth factors like IL-3, GM-CSF, SCF, TPO, and/or M-CSF, as well as others (Wunderlich et al, 2010; Rongvaux et al, 2014).”
BackgroundStebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 1×
“Dendritic cells (DCs) are main orchestrators of the adaptive immune system presenting processed peptide antigens to T cells through MHC classes I/II and expressing key costimulatory molecules such as CD40 ligand (CD40L) required for B-cell activation and class switching (Steinman, 2012).”
BackgroundBility, M. T., Cheng, L., Zhang, Z., Luan, Y., Li, F., Chi, L., Zhang, L., Tu, Z., Gao, Y., Fu, Y., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004032 · Cited by 227
Billerbeck, E., Mommersteeg, M. C., Shlomai, A., Xiao, J. W., Andrus, L., Bhatta, A., Vercauteren, K., Michailidis, E., Dorner, M., Krishnan, A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.022 · Cited by 87 · cited 2×
“Nevertheless, HBV and HCV infections have been explored in HIS mice with allogeneic or autologous hepatocyte engraftment (Washburn et al, 2011; Billerbeck et al, 2016; Dusseaux et al, 2017).”
Background
Cited by
Humanized mouse models for immuno-oncology research
Chuprin, J., Buettner, H., Seedhom, M. O., Greiner, D. L., Keck, J. G., Ishikawa, F., Shultz, L. D., & Brehm, M. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00721-2 · Cited by 423
Self-citationPatient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
“Several international PDX repositories have been set up in recent years, and guidelines describing the minimal information for the standardization of PDXs (PDX-MI) [84] or humanized mice (MISHUM) [37] were set forth.”
BackgroundAlternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“32 The introduction of human genes can be for the whole body, e.g., via microinjection of a plasmid or using promiscuous viral vector such as Sendai virus into embryos, 33,34 or tissue-specific, such as AAV9 for heart specific introduction of transgenes.”
Background
Metadata
- Authors
- Stripecke, R., Münz, C., Schuringa, J. J., Bissig, K., Soper, B., Meeham, T., Yao, L., Di Santo, J. P., Brehm, M., Rodriguez, E., Wege, A. K., Bonnet, D., Guionaud, S., Howard, K. E., Kitchen, S., Klein, F., Saeb‐Parsy, K., Sam, J., Sharma, A. D., Trumpp, A., Trusolino, L., Bult, C., & Shultz, L.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-06-24
- Volume
- 12
- Issue
- 7
- Pages
- e8662-e8662
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3037466102
- Cited by
- 137
- References
- 11
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.